These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 29780609)
1. Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosis. Lechner P; Buck D; Sick L; Hemmer B; Multhoff G Mult Scler J Exp Transl Clin; 2018; 4(2):2055217318767192. PubMed ID: 29780609 [TBL] [Abstract][Full Text] [Related]
2. Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease. McDonnell GV; McMillan SA; Douglas JP; Droogan AG; Hawkins SA J Neurol; 1999 Feb; 246(2):87-92. PubMed ID: 10195402 [TBL] [Abstract][Full Text] [Related]
3. Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. Malhotra S; Fissolo N; Tintoré M; Wing AC; Castilló J; Vidal-Jordana A; Montalban X; Comabella M J Neuroinflammation; 2015 Mar; 12():48. PubMed ID: 25879961 [TBL] [Abstract][Full Text] [Related]
4. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354 [TBL] [Abstract][Full Text] [Related]
6. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630 [TBL] [Abstract][Full Text] [Related]
7. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study. Blinkenberg M; Kjellberg J; Ibsen R; Magyari M Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969 [TBL] [Abstract][Full Text] [Related]
8. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis. Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645 [TBL] [Abstract][Full Text] [Related]
9. Involvement of cytotoxic Eomes-expressing CD4 Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594 [TBL] [Abstract][Full Text] [Related]
10. Utility of an untargeted metabolomics approach using a 2D GC-GC-MS platform to distinguish relapsing and progressive multiple sclerosis. Datta I; Zahoor I; Ata N; Rashid F; Cerghet M; Rattan R; Poisson LM; Giri S bioRxiv; 2024 Feb; ():. PubMed ID: 38370675 [TBL] [Abstract][Full Text] [Related]
11. Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis. Antonelou RCh; Emmanouilidou E; Gasparinatos G; Velona T; Voumvourakis KI; Stefanis L J Neurochem; 2015 Aug; 134(4):748-55. PubMed ID: 25962981 [TBL] [Abstract][Full Text] [Related]
12. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Liu B; Shen Y; Xiao K; Tang Y; Cen L; Wei J Neurol Res; 2012 Mar; 34(2):163-71. PubMed ID: 22333889 [TBL] [Abstract][Full Text] [Related]
13. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population. Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679 [TBL] [Abstract][Full Text] [Related]
14. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis. Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573 [TBL] [Abstract][Full Text] [Related]